Status:
COMPLETED
Antiviral Drugs on the Treatment of SARS-CoV-2
Lead Sponsor:
Astana Medical University
Conditions:
Complication of Medical Care
Pneumonia, Viral
Eligibility:
All Genders
18+ years
Brief Summary
Retrospective Non-Randomized Analytical Cohort Study of Completed SARS-CoV2 COVID19 Cases
Detailed Description
Analyzing the case histories of patients with SARS-CoV2 COVID19 infection and the impact on the outcomes of prescribing antiviral drugs
Eligibility Criteria
Inclusion
- main group
- Patients with COVID19 with medium and easy condition disease
- take favipiravir/remdisivir control group
- Patients with COVID19 with medium and easy condition disease
- not take favipiravir/remdisivir
Exclusion
- patients younger 18
- severe conditionis
Key Trial Info
Start Date :
December 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 25 2023
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT04727775
Start Date
December 1 2020
End Date
July 25 2023
Last Update
August 2 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Aidos Konkaev
Astana, Kazakhstan, 010000
2
Semey Medical University
Semey, Kazakhstan, 071407